Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 2

Status

Terminated 4Completed 4

Sponsor Class

INDUSTRY 6OTHER 2

Study Type

Interventional 8

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Other solid neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Cancers 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Interventional × Has results × ridaforolimus × Clear all
NCT01169532 2021-02-21

Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma

Fox Chase Cancer Center

Phase 1 Completed
16 enrolled 7 charts
Lymphoid

Lymphoma

NCT01212627 2021-02-16

Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer

Brown University

Phase 1 Terminated
12 enrolled 7 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00874731 2019-05-06

MK-8669-037

Merck Sharp & Dohme LLC

Phase 1 Completed
23 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01380184 2019-04-19

MK-8669-059

Merck Sharp & Dohme LLC

Phase 1 Completed
15 enrolled 15 charts

Neoplasms, Recurrence

NCT01605396 2019-03-25

MK-8669-064

Merck Sharp & Dohme LLC

Phase 2 Completed
80 enrolled 13 charts
Breast

Breast Neoplasms

NCT01431534 2019-03-01

MK-8669-056

Merck Sharp & Dohme LLC

Phase 1 Terminated
20 enrolled 10 charts
Other solid neoplasm

Solid Tumors

NCT00836927 2019-02-18

MK-8669-038

Merck Sharp & Dohme LLC

Phase 2 Terminated
7 enrolled 13 charts

Advanced Cancers

NCT01243762 2018-08-16

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Merck Sharp & Dohme LLC

Phase 1 Terminated
47 enrolled 12 charts
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡